On April 30, 2026, a trial update was recorded for a study involving pasireotide, registered as NCT06784752. The study is titled "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET." The trial is listed as Phase 3 and is currently in recruiting status as of this update.
The registration indicates the study is designed to evaluate efficacy and safety outcomes in patients with Grade 1 and Grade 2 advanced gastroenteropancreatic neuroendocrine tumors, known as GEP-NET. No results have been posted as part of this update, and the data provided do not describe specific endpoints, enrollment numbers, or interim findings.
Pasireotide is an approved compound, and its role in this specific trial record is noted without further detail in the available data. As the study continues in its recruiting phase, additional information may become available through future updates to the trial registration.
Readers seeking general background on pasireotide can consult the compound overview for additional context.